Clinical Trials

Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases (including multiple sclerosis (MS), Graves' disease and uveitis), announced positive results from the Phase I first in man clinical trial of its product candidate, ATX-GD-59,...

The U.S. FDA  approved Sanofi's Toujeo® (insulin glargine 300 Units/mL) Max SoloStar®, the highest capacity long-acting insulin pen that will be available on the market. The new Max SoloStar pen holds 900 Units of Toujeo, more...

GeNeuro and Servier announced positive results at 12 months from the CHANGE-MS Phase 2b study of GNbAC1, a novel and promising therapeutic approach for the treatment of multiple sclerosis (MS). The data showed that GNbAC1 administration...

Alexion Pharmaceuticals, Inc. announced that the pivotal Phase 3 study of ALXN1210, the Company’s investigational long-acting C5 complement inhibitor, demonstrated non-inferiority to Soliris® (eculizumab) in complement inhibitor treatment-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH) based on the co-primary endpoints...

Medigene AG , a clinical stage immune-oncology company focusing on the development of T cell immuno-therapies for the treatment of cancer, announces the grant of European patent EP2327763, a member of Medigene's core patent family concerning the company's allo-restricted...

U.S. drug developer Aimmune Therapeutics said on Tuesday its peanut allergy drug met the main goal of an eagerly awaited late-stage study, sending its shares up 18 percent premarket. The positive trial data comes nearly four...

Clinical response was defined as menstrual blood loss volume of less than 80 mL during month six and a 50 percent or greater reduction in menstrual blood loss volume from baseline to month six. The study also met all...